CordenPharma ups Swiss API development services

By Staff Reporter

- Last updated on GMT


Related tags Capital accumulation Investment

CordenPharma has invested in its Swiss API development services a week after buying a manufacturing plant from Pfizer.

The contract development and manufacturing organisation (CDMO) said it is investing €3.7m ($4.4m) into its site in Liestal, Switzerland to increase its small molecule development services and refurbish its purification capabilities.

Around €2m of the investment will be used to add automation equipment at the plant “to facilitate development services and an extensive upgrading and expansion of analytical equipment,”​ the firm said. But despite the automation tech, the firm expects an increase in the overall number of development staff.

The rest of the investment will be used to build a mini-plant and refurbish current purification capabilities at the site, to meet growing market demands in the g to kg’s range and at a scale of 1-70 liters, the firm said.

“The introduction of this new mini-plant will enable us to run small-scale batches for our customers, while at the same time demonstrating the routes readiness for further scale-up and addressing their material requirements for early-phase clinical stages,”​ Juerg Burger, managing director of CordenPharma Switzerland, said in a press release.

The expansion comes a week after the CDMO announced it was buying a highly potent active pharmaceutical ingredient (HPAPI) plant from Pfizer​ in Boulder, Colorado.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more